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Abstract
Background: Epidemiological and pedigree studies suggest that lung cancer results from the combined effects of age,
smoking, impaired lung function and genetic factors. In a case control association study of healthy smokers and lung cancer
cases, we identified genetic markers associated with either susceptibility or protection to lung cancer.
Methodology/Principal Findings: We screened 157 candidate single nucleotide polymorphisms (SNP) in a discovery cohort
of 439 subjects (200 controls and 239 lung cancer cases) and identified 30 SNPs associated with either the healthy smokers
(protective) or lung cancer (susceptibility) phenotype. After genotyping this 30 SNP panel in a validation cohort of 491
subjects (248 controls and 207 lung cancers) and, using the same protective and susceptibility genotypes from our
discovery cohort, a 20 SNP panel was selected based on replication of SNP associations in the validation cohort. Following
multivariate logistic regression analyses, including the selected SNPs from runs 1 and 2, we found age and family history of
lung cancer to be significantly and independently associated with lung cancer. Numeric scores were assigned to both the
SNP and demographic data, and combined to form a simple algorithm of risk.
Conclusions/Significance:Significant differencesinthe distributionofthelung cancersusceptibilityscore wasfound between
normal controls and lung cancer cases, which remained after accounting for differences in lung function. Validation in other
case-control and prospective cohorts are underway to further define the potential clinical utility of this model.
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Introduction
While 90% of people with lung cancer have a smoking history,
only 10–15% of chronic smokers develop lung cancer suggesting
factors in addition to smoking exposure are relevant [1].
Age,smoking exposure, impaired lung function and family history
have been identified as independent risk factors for lung cancer
[2]. Genetic factors have also been shown to play a role in
determining susceptibility to lung cancer [3]. These genetic factors
are believed to confer an inherent susceptibility (exaggerated or
maladaptive response) to chronic inflammation from cigarette
smoking [4,5]. Consistent with many cancer models, this
inflammatory stimulus in the lungs results in tissue remodeling,
DNA damage and impaired cell cycle control [3–5]. This tissue
remodeling results in impaired lung function (ie chronic
obstructive pulmonary disease or COPD) that, despite affecting
the minority of smokers [6], is present in 50% or more of lung
cancer cases [7] and recognized as one of the most important
markers of lung cancer risk [8].
Genetic predisposition to lung cancer is likely to be both
polygenic and heterogeneous, conferred by a variable combination
of relatively common polymorphisms with low penetrance and
modest effect sizes [9,10]. Moreover, it is likely that important
smoking-gene interactions underlie lung cancer [11] as seen in
other smoking-related cancers (e.g. bladder and stomach). Genetic
variants associated with both COPD and lung cancer have been
identified, most recently the chromosome 15q25 gene locus
[12,13]. Therefore to avoid possible confounding we suggest it is
important to measure lung function in participants of case-control
studies of lung cancer [13]. For both epidemiological and
biostatistical reasons, spirometric screening of comparably exposed
controls will increase the power of the study to identify relevant
genetic variants (distinguishing low from high risk people)
compared to studies where the control group is unscreened [14].
It is well known that non-genetic risk factors such as age, history
of lung disease and smoking history are very important and can be
combined to develop risk based tools for lung cancer susceptibility
such as the Lung Cancer Assessment Tool developed by Bach
(www.mskcc.org) [15]. Recently, genotype data from previously
implicated prostate cancer susceptibility SNPs were combined
with family history to derive risk estimates for prostate cancer [16].
In the latter study, controls were screened using prostate specific
antigen and only those with normal levels were recruited as
controls. This approach minimizes misclassification of controls (ie
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prostate cancer). We have used a similar approach in our case
control study design and analysis, and show how genetic variants
previously showing small effects on lung cancer risk can be
combined in an algorithm with other known risk factors to derive a
risk model for lung cancer.
Methods
Study Population
This study was a two stage case control design conducted in 3
centers following the same recruitment protocol. Lung cancer
cases of Caucasian ancestry (all 4 grandparents of Caucasian
descent) were identified through hospital clinics between 2004 and
2007 as follows: .40 yrs of age, past history of smoking (minimum
15 pack years), diagnosis confirmed on histological or cytological
grounds and limited to the following 4 histological subtypes-
adenocarcinoma, squamous cell cancer, small cell cancer and non-
small cell cancer (generally large cell or bronchoalveolar subtypes).
The median time interval between diagnosis and recruitment was
3 months. Lung cancer cases underwent blood sampling for DNA
extraction, an investigator administered questionnaire and spi-
rometry using a portable spirometer (Easy-One
TM, ndd Medizin-
technik AG, Switzerland) following American Thoracic Society
(ATS) criteria. For those lung cancer cases who had already
undergone surgery, pre-operative lung function performed by the
hospital laboratory (using ATS criteria) was sourced from the
medical records.
Control subjects were recruited from the same communities as
the cases as follows: Caucasian ancestry (as defined above), aged
45–80 yrs old and had a past or current smoking history of a
minimum of 15 pack years. Controls were volunteers who met the
above criteria and were identified through either a community
mail out or while attending community based social clubs. All
smoking controls underwent blood sampling, spirometry and the
same investigator administered questionnaire given to lung cancer
cases. Control smokers recruited from the community that were
found to have COPD, based on screening spirometry (FEV1/
FVC,70% and FEV1 % predicted ,80%), were analysed
separately. All subjects provided informed written consent. The
study was approved by the Multi-Region Ethics Committee,
Wellington, New Zealand (AKX/03/08/207). The questionnaire
(modified from the ATS respiratory questionnaire) included data
on demographic variables such as age, gender, medical history,
family history of lung disease, active and passive tobacco exposure
and occupational aero-pollutant exposures.
Selection and genotyping of single nucleotide
polymorphisms
Following literature review, polymorphisms previously impli-
cated in either COPD or lung cancer with the following attributes
were selected: (a) single nucleotide polymorphisms (SNPs) in genes
encoding proteins in pathways of cell-cycle control, oxidant
response, apoptosis and airways inflammation and (b) SNPs that
were known to have either functional effects on in vitro assays, or
were non-synonymous or in regulatory regions. In a discovery
cohort of 439 smokers (run 1 recruited during the years 2003–
2005: 239 lung cancer cases and 200 control smokers), 157
candidate SNPs were screened (see supplementary data S1) and
those where the difference in genotype frequencies between cases
and controls (using recessive or co-dominant model) exceeded a
20% magnitude difference and P value ,0.20 were identified as
part of our model forming approach [17]. SNPs with call rates
,95% after retesting, were not included in further analysis. SNPs
were assigned as ‘‘protective’’ or susceptible when the homozygote
and/or heterozygote genotype for either allele were found in
excess in control smokers or lung cancer cases respectively (in a
recessive or co-dominant model).
Genotyping
Genomic DNA was extracted from whole blood samples using
standard salt based methods. Purified genomic DNA was aliquoted
(10 ng/ul concentration) into 96 well plates and genotyped on a
Sequenom
TM system (Sequenom
TM Autoflex Mass Spectrometer
and Samsung 24 pin nanodispenser) by the Australian Genome
Research Facility (www.agrf.com.au) using sequences designed in
house (available on request) and recommended amplification and
separation methods (iPLEX
TM, www.sequenom.com) [16].
From the 157 candidate SNPs screened in our discovery cohort
(see supplementary data S1), 30 SNPs met the above criteria in run
1. These 30 SNPs were genotyped in a second validation cohort of
491 smokers (run 2 recruited during the years 2006–2007: 207
lung cancer cases and 284 control smokers) recruited in the same
way. For all SNP assays, again a minimum of 95% call rate was
required. This second cohort of lung cancer cases and healthy
control smokers were comparable to the first groups in respect to
demographic factors and lung cancer characteristics (unpublished
data). Based on independent replication of the associations
(univariate analyses with similar OR and P values) in run 2 as
observed in run 1 (ie. consistency, direction and significance of
association), a final panel of the 20 most discriminatory SNPs (12
susceptibility SNPs and 8 protective SNPs from the test panel of
30) was selected (see supplementary data S1).
Algorithm
The assignment of a protective or susceptible SNP genotype/s
was made from the test cohort data (run 1) and was strictly applied
to the data from run 2. For each subject, a numerical value of 21
was assigned for each of the protective genotypes present among
the protective SNPs and +1 for each of the susceptible genotypes
present. Where an individual did not have either the protective or
susceptibility genotype for that SNP the score was 0 (ie. did not
contribute to the genetic score). This approach is consistent with a
recently published study in prostate cancer [16]. Weighting the
presence of specific susceptible or protective genotypes according
to their individual odds ratios (OR from univariate regression or
point estimates from multivariate regression) did not significantly
improve the discriminatory performance of the raw SNP score
(unpublished data).
Lung cancer susceptibility score
Using multivariate logistic and stepwise regression analysis from
run 1, the SNPs were examined along with relevant non-genetic
factors which identified age and family history of lung cancer as
significant contributors to lung cancer susceptibility. Consistent
with other case control studies, previously diagnosed COPD and
female gender in our study were also associated with an increased
risk of lung cancer (p,0.001 and p,0.01 respectively). We did not
include gender in the final risk model as its importance in
prospective studies is lacking [18]. We did not include COPD in
the model as this was the basis of selecting our controls. Based on
the multivariate analysis in run 1, a score was assigned according
to age and family history and tested in run 1 and run 2 separately
in a receiver operator curve analysis (ROC, see results below).
These two variables have been identified in other risk assessment
tools for lung cancer susceptibility [15] and improved the
discriminatory power of the SNP score data alone. As smoking
exposure (pack years) was a recruitment criteria for this study and
Lung Cancer Risk Model
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find it made little contribution to this scoring system derived from
our cohorts. The lung cancer susceptibility score for the combined
lung cancer cases and controls (n=930) was plotted with (a) the
frequency of lung cancer, and (b) the floating absolute risk
(equivalent to odds ratio) across the combined smoker/ex-smoker
cohort [19,20].
Statistical analysis
Patient characteristics in the cases and controls were compared
by unpaired t-tests for continuous variables and chi-square test for
discrete variables. Genotype and allele frequencies were checked
for each SNP by Hardy Weinberg Equilibrium (HWE). Population
admixture was excluded by the Population structure analysis on
genotyping data from 40 unrelated SNPs [21]. Distortions in the
genotype frequencies were identified between cases and controls
using 2 by 3 contingency tables. Genotype data (20 SNP panel)
and the most relevant non-genetic variables were combined in a
stepwise fashion to assess their combined effects on discriminating
low and high risk (by odds ratio and ROC) by score quintile. The
frequency distribution of the optimized lung cancer susceptibility
score was compared across the cases and controls. It’s potential
clinical utility as a risk tool was assessed using receiver-operator
curve analysis.
Results
Demographic variables and genotyping
Characteristics of the healthy control smokers, and lung cancer
cases are summarized in Table 1. The 446 lung cancer cases (run
1=239 and run 2=207) were comparable to a recently published
series [22]. Given the small difference in age, the 482 healthy
control smokers (run 1=200 run 2=282) were comparably
exposed with respect to smoking and other aero-pollutants. The
lower frequency of current smokers in the lung cancer group likely
reflects co-existing COPD (higher quit rates) while longer duration
of smoking in lung cancer cases reflects their older age. In a gene
by smoking interaction model such as this, differences in smoking
exposure are more likely to obscure effects (bias to the null) than
generate effects. Consistent with the findings of others, the lung
cancer cohort had higher rates of a family history of lung cancer
(19% vs 9%) and history of COPD (29% vs 5%). The latter (5%)
most likely reflects a clinical diagnosis of COPD, based on
symptoms but not spirometry, in smokers with asthma and/or
Table 1. Summary of characteristics for the Lung cancer and healthy control smokers.
Parameter Lung Cancer N=446 Healthy control smokers N=484 P value for differences
Characteristics (% or mean (1SD))
% male 53% 60% 0.007
Age (yrs) 69 (10) 60 (10) ,0.001
Height (cm) 167(0.08) 170 (0.09) ,0.001
Weight (kg) 69 (15) 79(15) ,0.001
History of COPD 29% 5% ,0.001
Smoking History
Current smoking (%) 35% 48% ,0.001
Age started (yr) 18 (4) 17 (3) ,0.001
Yrs smoked 41 (12) 35 (11) ,0.001
Pack years 41 (25) 40 (19) 0.28
Cigarettes/day 20 (10) 24 (11) ,0.001
History of other exposures
In utero smoke exposure 18% 17% ns
Mother smoked in childhood 37% 41% 0.03
Home ETS exposure as adult 79% 58% ,0.001
Work ETS exposure 86% 63% ,0.001
Work dust exposure 63% 47% ,0.001
Work fume exposure 41% 38% 0.16
Asbestos exposure 23% 16% 0.02
Family History
FHx of COPD 33% 28% 0.12
FHx of lung cancer 19% 9% ,0.001
Lung function
FEV1 (L) 1.86 (0.48) 2.86 (0.68) ,0.001
FEV1 % predict 73% 99% ,0.001
FEV1/FVC 64 (13) 78 (7) ,0.001
Spirometric COPD* 51% 0% ,0.001
ETS=environmental tobacco smoke.
*According to GOLD 2+ criteria.
doi:10.1371/journal.pone.0005302.t001
Lung Cancer Risk Model
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lung cancer cohort compared to the healthy smoker controls.
Testing lung function in the lung cancer cases (performed within 3
months of diagnosis, in the absence of pleural effusions and prior
to surgery) allows us to test for confounding by COPD (see below).
Based on replication of association in run 1 and independently
in run 2, the 20 most consistently associated SNPs were selected.
The observed genotypes for the 20 SNPs in this study were in
Hardy-Weinberg equilibrium (see Table 2) thereby excluding
significant genotyping error. The genotype frequencies for the
controls were comparable to those from the International Hapmap
Project (www.hapmap.org). The development of the lung cancer
susceptibility score is described in methods above and a summary
of the 20 SNP panel univariate analysis is presented in Table 3.
Although 6 of the top 20 SNPs do not reach traditional levels of
significance they have been included in the panel because (a) in
previous studies they have been shown to have functional effects
(b) they have been previously associated with COPD and/or lung
cancer (see discussion), (c) in combination they make a
contribution to the performance of the susceptibility score (AUC
for the model including only the 14 significant SNPs P#0.05, see
below), and (d) their inclusion allows for the genetic heterogeneity
that exits in lung cancer case control studies.
Risk model development
In a multivariate logistic regression analysis that included the
selected SNPs (individually), age (.60 yrs), family history of lung
cancer (first degree relative), gender and history of COPD were
found to be independently associated with lung cancer suscepti-
bility in run 1, run 2 and combined. For the combined data set,
OR for the susceptibility and protective SNPs ranged between
1.1–3.2 and 0.20–0.80 respectively (the combined SNP score is
independently related to lung cancer, P,0.001). The OR for
age.60 yrs and family history of lung cancer were 3.5 (2.5–4.9,
p,0.001) and 2.5 (1.6–4.0, p,0.001) respectively (total
AUC=0.75 where SNPs were included individually while
adjusting for the non-genetic variables). Based on these findings,
and those from previously published studies [3,6,7], we assigned
scores to non-genetic variables as follows; +4 for those aged
.60 yrs old and +3 for those with a family history of lung cancer.
Such an approach is consistent with existing risk scores [15,16]
and places the SNP data in appropriate clinical context [15].
Gender and diagnosed COPD were not included in this risk model
for the reasons described above.
Model performance
In the combined 20 SNP model, the lung cancer susceptibility
score was compared with frequency of lung cancer and a linear
relationship was found across the lung cancer susceptibility scores #1
to 8+ with lung cancer frequency spanning 18% to 81% (figure 1a).
The magnitude of this effect was also examined using the floating
absolute risk [19,20] plotted on a log scale (equivalent to an Odds
ratio, OR), which references the lowest frequency group as OR=1
(referent group, lung cancer score #1) and compares each lung
cancer score relative to the referent group (Figure 1b). The OR
spanned from 1 to 19.1 across the lung cancer scores when subjects
were grouped approximately as quintiles (p,0.001). The lung cancer
susceptibility score for lung cancer cases and controls shows a
Table 2. Expected genotype frequencies and Hardy Weinberg Equilibrium.
SNP # SNP Name rs number Allele frequencies
HWE observed
genotypes P value Allele frequencies Allele frequencies
Study total (n=930) Study controls (n=484) Hapmap –Caucasian*
Major Minor Major Minor Major Minor
1 a5 nAChR rs16969968 0.65 0.35 0.57 0.69 0.31 0.58 0.42
2 CYP 2E1 rs2031920 0.98 0.02 0.06 0.99 0.01 0.94 0.06
3 Interleukin-18 rs360721 0.70 0.30 0.77 0.68 0.32 0.70 0.32
4 Interleukin-8 rs4073 0.54 0.46 0.14 0.51 0.49 0.60 0.40
5 Interleukin 1B rs16944 0.69 0.31 0.80 0.67 0.33 0.65 0.35
6 ITGA11 rs2306022 0.90 0.10 0.07 0.91 0.09 0.93 0.07
7 NAT 2 rs1799930 0.71 0.29 0.87 0.69 0.31 0.71 0.29
8 a1-antichymotrypsin rs4934 0.50 0.50 0.54 0.47 0.53 0.51 0.49
9 Cerberus 1 rs10115703 0.92 0.08 0.54 0.93 0.07 0.89 0.11
10 DAT1 rs6413429 0.93 0.07 0.78 0.94 0.06 0.87 0.13
11 TNFR1 rs1139417 0.57 0.43 0.96 0.56 0.44 0.51 0.49
12 TLR9 rs5743836 0.85 0.15 0.92 0.85 0.15 0.84 0.16
13 P73 (TP73) rs2273953 0.75 0.25 0.93 0.78 0.22 0.85 0.15
14 SOD3 rs1799895 0.99 0.01 0.99 0.98 0.02 0.97 0.03
15 ITGB3 rs2317676 0.93 0.07 0.51 0.91 0.09 0.95 0.05
16 DRD2 rs1799732 0.90 0.10 0.67 0.89 0.11 0.90 0.10
17 BCL2 rs2279115 0.51 0.49 0.60 0.53 0.47 0.57 0.43
18 XPD (ERCC2) rs13181 0.61 0.39 0.90 0.59 0.41 0.67 0.33
19 REV1 (REV1L) rs3087386 0.56 0.44 0.96 0.58 0.42 0.50 0.50
20 FasL (TNFSF6) rs 763110 0.63 0.37 0.83 0.61 0.39 0.64 0.36
*allele frequencies for Caucasians from www.hapmap.org.
doi:10.1371/journal.pone.0005302.t002
Lung Cancer Risk Model
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potential utility as a screening test of risk [23].
Model sensitivity analysis
To correct for the small differences in age, smoking status and
gender mix between cases and controls, a subgroup (sensitivity)
analysis was done (a) limited to those over 60 years of age (age
weighting equally applied to all) and (b) where mean age, pack
years and gender were closely matched between cases and controls
(n=450: 72 vs 69 yrs, 45 vs 43 pack years and 70% vs 70% male
respectively). A linear increase in OR across quintiles of the lung
cancer susceptibility score (range 1–28, p,0.01) remained evident
Table 3. Genotypes and results of regression analysis.
SNP * Rs number Genotype
LungCancer
N( % )
Smoking
Contr N (%)
Call
rate
Univariate OR
(95% CI) P value Phenotype
a5-nAChR rs16969968 AA 68 (16%) 45 (9%) 98% 1.8 (1.2–2.7) 0.004 susceptibility
AG/GG 361 (84%) 426 (91%)
CYP 2E1 rs2031920 TT/TC 24 (6%) 14 (3%) 95% 2.1 (1.0–4.3) 0.03 susceptibility
CC 379 (94%) 463 (97%)
Interleukin-18 rs360721 CC 237 (54%) 208 (45%) 96% 1.4 (1.1–1.9) 0.009 susceptibility
CG/GG 201 (46%) 250 (55%)
Interleukin-8 rs4073 TT 129 (31%) 109 (23%) 96% 1.5 (1.1–2.1) 0.005 susceptibility
AT/AA 284 (69%) 367 (77%)
Interleukin 1B rs16944 GG 215 (49%) 212 (44%) 99% 1.2 (0.9–1.6) 0.14 susceptibility
AA/AG 224 (51%) 269 (56%)
ITGA11 rs2306022 AA 14 (3%) 6 (1%) 98% 2.6 (0.9–7.6) 0.04 susceptibility
GA/GG 422 (97%) 470 (99%)
N–acetylcysteine
transferase 2
rs1799930 GG 239 (56%) 222 (47%) 97% 1.4 (1.1–1.9) 0.006 susceptibility
AA/AG 189 (44%) 253 (53%)
a1-antichymotrypsin rs4934 GG 123 (28%) 96 (20%) 98% 1.6 (1.2–2.2) 0.004 susceptibility
AG/AA 312 (72%) 383 (80%)
Cerberus 1 rs10115703 AA/AG 71 (16%) 59 (12%) 97% 1.4 (0.9–2.0) 0.10 susceptibility
GG 363 (84%) 413 (88%)
DAT1 rs6413429 GT/TT 64 (15%) 50 (10%) 98% 1.5 (1.0–2.3) 0.04 susceptibility
GG 367 (85%) 431 (90%)
TNFR1 (TNFRSF1A) rs1139417 AA 148 (36%) 142 (30%) 96% 1.3 (1.0–1.8) 0.05 susceptibility
AG/GG 258 (64%) 329 (70%)
TLR9 rs5743836 CC 12 (3%) 6 (1%) 96% 2.2 (0.8–6.6) 0.12 susceptibility
CT/TT 419 (97%) 455 (99%)
P73 (TP73) rs2273953 CC 219 (52%) 292 (62%) 96% 0.65 (0.49–0.85) 0.001 protective
TC/TT 206 (48%) 178 (38%)
SOD3 rs1799895 GG/GC 4 (1%) 15 (3%) 96% 0.28 (0.10–0.90) 0.02 protective
CC 425 (99%) 451 (97%)
ITGB3 rs2317676 GG/GA 44 (10%) 77 (16%) 98% 0.59 (0.39–0.89) 0.008 protective
AA 391 (90%) 403 (84%)
DRD2 rs1799732 CDel/Del.Del 70 (16%) 107 (22%) 98% 0.68 (0.48–0.96) 0.02 protective
CC 359 (84%) 372 (78%)
BCL2 rs2279115 AA 103 (24%) 145 (31%) 97% 0.71 (0.53–0.97) 0.03 protective
AC/CC 328 (76%) 330 69%)
XPD (ERCC2) rs13181 GG 60 (14%) 81 (18%) 96% 0.74 (0.51–1.10) 0.11 protective
GT/TT 376 (86%) 377 (82%)
REV1 (REV1L) rs3087386 CC 128 (29%) 163 (34%) 98% 0.79 (0.59–1.10) 0.10 protective
TC/TT 310 (71%) 312 (66%)
FasL (TNFSF6) rs 763110 TT 53 (12%) 78 (16%) 98% 0.72 (0.49–1.10) 0.09 protective
TC/CC 379 (88%) 403 (84%)
*(OMIM nomenclature).
doi:10.1371/journal.pone.0005302.t003
Lung Cancer Risk Model
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derived using the full data set (figure 1b). The potential
confounding effect of COPD was also examined by (a) comparing
the distribution of the lung cancer susceptibility score in lung
cancer cases according to spirometric criteria (% predicted FEV1,
Figure 3a) and (b) excluding lung cancer cases with co-existing
COPD (based on previously described spirometric criteria n=227,
Figure 3b). The distribution of the scores among cancer cases sub-
grouped according to lung function or COPD are not different to
the total lung cancer cohort (Figures 3a and 3b) and exclude
significant confounding by COPD.
ROC analysis
In a receiver operator curved analysis (n=930) of the combined
20 SNP model, we found the area under the curve (AUC or C
statistic) for run 1, run 2 and run 1+2 was 0.82, 0.75 and 0.77
respectively.TheAUCinthe totalcohortforthe20SNPpanel,age,
and family history of lung cancer on their own were 0.68, 0.70 and
0.55 respectively.When ‘‘geneticfactors’’only areutilised inthe risk
model (SNPs+FHx of lung cancer), as seen in the Prostate cancer
study [16], the OR spans 1–10 across quintiles and the AUC=0.70
(with no contribution from age). On stepwise analysis, age and the
SNP panel make the greatest contribution to the AUC
(SNPs=0.68, age+SNPs=0.76 and age+SNPs+FHx=0.77). When
the SNP panel is limited to the 14 significant SNPs, the AUC for the
SNPs alone is 0.66 and when combined with age and family history
is 0.75. When gender was included in the 20 SNP combined model
the AUC was not improved. When past history of COPD was also
added to the combined model (scoring +4 based on multivariate
regression), the AUC increased to 0.79. As stated above, when age
and pack years were stringently matched and possible confounding
by COPD analysed, there was no difference in our findings.
Discussion
Using a candidate gene approach in a two stage selection
process a panel of protective and susceptibility SNPs were
Figure 1. 1a. Frequency of lung cancer according to the lung cancer susceptibility (risk) score. 1b. Odds ratio of lung cancer according to the lung
cancer susceptibility (risk) score.
doi:10.1371/journal.pone.0005302.g001
Figure 2. Frequency distribution of the lung cancer susceptibility (risk) score in cases and controls.
doi:10.1371/journal.pone.0005302.g002
Lung Cancer Risk Model
PLoS ONE | www.plosone.org 6 April 2009 | Volume 4 | Issue 4 | e5302identified that individually confer only small effects on risk of lung
cancer (OR ranging from 0.3 to 2.6). This is very much in keeping
with the experience from case control association studies to date
[11,12,16,24]. Consistent with existing risk models, relevant
factors were combined using an algorithm (in this study including
SNP data) to derive a susceptibility score on a simple linear scale.
This study design, and the algorithmic approach that underlies this
lung cancer susceptibility score, is comparable to a recent study in
prostate cancer. Moreover, it takes into account important
epidemiological observations relevant to genetic predisposition to
Figure 3. 3a Frequency distribution of the lung cancer score among controls and lung cancer cases divided according to low (COPD) and normal
lung function. 3b Frequency distribution of the lung cancer score among controls and lung cancer cases with normal lung function (COPD excluded).
doi:10.1371/journal.pone.0005302.g003
Lung Cancer Risk Model
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pre-requisite to getting lung cancer, increasing age and poor lung
function have important independent effects on lung cancer
susceptibility. Second, the genetic factors underlying lung cancer
risk are likely to be both polygenic and heterogeneous, conferred
by a variable combination of genetic variants (i.e. SNPs with low
penetrance and small effect sizes). Third, genetic factors may
confer either a protective [24] or susceptibility [13] phenotype to
lung cancer. Fourth, the potential confounding effect of COPD
[13] has been accounted for in the model. Here we report a 20
SNP panel which combined with family history [16] define risk
(OR) across quintiles ranging 1–10 with an AUC of 0.70. A risk
tool with greater clinical utility can be derived by including age to
identify those at greatest susceptibility to lung cancer (OR ranging
1–19 and AUC=0.77).
Thisstudysoughtto minimize false positiveresults ina numberof
ways. The most important of these was to internally validate the
SNP associations using a two stage design with an initial discovery
cohort(run1)toidentifySNPsofpotentialinterest.OnlytheseSNPs
were tested in a second (validation) cohort of cases and controls (run
2) and using univariate analysis from the two runs independently to
select the SNPs based on replication. Second, population stratifi-
cation was excluded and third, the presence of genotyping error was
minimized through HWE analysis and by the exclusion of SNPs
with ,95% call rate (fails on genotyping is invariably genotype
specific, thus generating false positive associations). With respect to
possible confounding, in a sensitivity analysis where lung cancer
cases and healthy smoking controls were matched for smoking
exposure (pack years), age, gender and presence of COPD, the
performance of the lung cancer score was not reduced.
Weaknesses in this study include the modest size of the cohorts,
borderline significance of some SNPs in the absence of correction,
cross-sectional design and recruitment limited to Caucasians with
a minimum 15 pack years. Furthermore, we chose to recruit
smokers with essentially normal lung function as controls to
improve power [14] and best represent those least susceptible to
the adverse effects of smoking (COPD and lung cancer) but most
representative of smokers in general who maintain normal lung
function [6]. For this reason, COPD was not included in the
model although it is an important risk factor and added to the
score’s utility in a post-hoc analysis. A further limitation of the
study is that although the cases and controls were arguably
representative, not all variables were precisely matched in the
initial analysis (eg age, gender and smoking patterns). It should be
noted that although precise matching of all demographic variables
reduces the potential for confounding, it also potentially obscures
important effects of variables in a risk model. Although only 14 of
the 20 SNPs reached traditional levels of significance in the
combined cohorts, and the addition of the remaining six SNPs
only contributed modestly to the model, this was a two stage
design where replication of associations (in this and other studies)
and biological plausibility [23–42] were the basis of SNP selection.
Further studies will need to be done to further validate this SNP
panel and risk model in unselected populations.
In this study a candidate gene (i.e. hypothesis driven) approach
was used to identify potentially functional SNPs associated with the
development of both COPD and lung cancer. Although the SNPs
identified in this study may only reflect linkage disequilibrium with
functional variants nearby, these SNPs are likely to have functional
effects and involvement directly with susceptibility to lung cancer.
The 20 SNP panel consists of genetic variants known to encode
proteins underlying important pathways implicated in lung
carcinogenesis, specifically; metabolism of smoking-derived carcin-
ogens (N-Acetyl Transferase 2 and Cytochrome P450 2E1) [25,26],
inflammatory cytokines (Interleukins 1, 8 and 18, Tissue necrosis
factor alpha1 receptor, Toll-like receptor 9) [27–30], smoking
addiction (dopamine D2 receptor and Dopamine transporter 1)
[31,32], anti-oxidant response to smoking (a1 anti-chymotrypsin
and extracellular superoxide dismutase) [24,33], cell cycle control,
DNA repair and apoptosis (Xeroderma Pigmentosum complemen-
tary group D, p73, Bcl-2, FasL, Cerb1 and REV1) [34–39] and
integrins implicated in apoptosis [40–42]. One of the SNPs (a5
nAChR) has recently been associated with both lung cancer and
COPD in candidate gene [13] and genome wide association studies
[43,44]. This receptor appears to de directly related to nicotine
effects on airway inflammation [45]. As can be seen, the SNP panel
(Table III) is made up of a variety of SNPs from genes implicated in
many inter-related pathways. Twelve of these SNPs have been
associated with lung cancer in other cohorts. It is likely other SNPs
from as yet unidentified genes will be identified in the future. To
assess further the utility of the lung cancer susceptibility score, a
prospective study is in progress. To date the lung cancer cases
(n=43) have the same mean and distribution as the lung cancer
cases reported in this study (unpublished data). Further case control
and functional studies will be needed to further explore the role of
these SNPs in lung cancer susceptibility.
The authors propose that clinical utility of genotype data
requires that many SNPs are analyzed and their effects combined
with other epidemiological factors of relevance [16]. The
algorithm approach used in this study assumes a simple additive
model comparable to that recently published in Prostate cancer
[16] and involves minimal assumptions (not hierarchical or Path
analysis based). The patient’s score can be compared with the
scores in smokers with least susceptibility to lung cancer (lowest
quintiles) in a simple linear fashion. Such an approach is
comparable to the risk tools developed by others [15,16]. The
potential clinical utility of the lung cancer susceptibility score was
assessed by receiver operator curve analysis. This showed the c
statistic to be 0.77 and, at a cut off of $3, an estimated sensitivity
of 89% and corresponding specificity of 45%. These findings are
comparable to the ROC performance of the Framingham score (c
statistic=0.74). The c statistic for the 20 SNP panel on its own was
0.68 (and 0.70 when combined with family history) indicating its
utility in the current cohort. There is evidence, although limited,
that genetic testing may positively alter the behavior of smokers in
the context of smoking cessation (increase intent and possibly
improve quit rate [46,47]) or by lowering smoking prevalence
[48]. Although further validation studies are required, this study
suggests that genetic data may be combined with other risk
variables from smokers or ex-smokers to identify individuals most
susceptible to developing lung cancer. Further studies are planned
in larger cohorts of unselected cases and controls.
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